Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients

Frontiers in Cardiovascular Medicine

Massimo Volpe¹  Costantino Mancusi²  Guido Iaccarino²  Davide Grassi³  Claudio Ferri³  Maria Lorenza Muiesan⁴  Massimo Salvetti⁴  Claudio Borghi⁵  Guido Grassi⁶ 

[1] Clinical and Molecular Medicine Department, Sapienza University, Rome, Italy;Sant'Andrea Hospital, Rome, Italy;Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy;Department of Clinical Medicine, Public Health, Life and Environment Sciences, University of L'Aquila, L'Aquila, Italy;Department of Clinical and Experimental Sciences, University of Brescia, Medicina 2, ASST Spedali Civili Brescia, Brescia, Italy;Department of Medicine and Surgery Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy;Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy;

关键词: multimorbidity;    atrial fibrillation;    prophylaxis;    death;    intensive care admissions;    COVID-19 outcomes;    hypertension;    thrombosys;   

DOI  :  10.3389/fcvm.2021.633878

来源: Frontiers

【 授权许可】

CC BY